Short answer
Intellia Therapeutics, Inc. (NTLA) filed an 8-K current report with the SEC on June 15, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Additional positive Phase 3 results for lonvoguran ziclumeran in hereditary angioedema.
Intellia Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Additional positive Phase 3 results for lonvoguran ziclumeran in hereditary angioedema
- Clinical update furnished June 13, 2026 under Regulation FD
- Results detailed in Exhibit 99.1, potentially relevant to lonvo-z’s development and regulatory prospects
Item 8.01 · Other Events
- Phase 3 HAELO reinforced lonvo-z efficacy, with 87% fewer monthly HAE attacks versus placebo
- 62% of lonvo-z patients were attack-free and therapy-free versus 11% on placebo
- Key secondary endpoints showed 89% fewer treated attacks and 91% fewer moderate/severe attacks
- Quality of life improved 17.04 points versus placebo, exceeding the 6-point clinically important threshold
- Rolling BLA submission began in April, with U.S. approval and launch anticipated in first half 2027
Item EX-99.1 · Exhibit EX-99.1
- Phase 3 HAELO data showed 87% fewer monthly attacks versus placebo, reinforcing lonvo-z’s potential as a one-time HAE treatment
- 62% of lonvo-z patients were attack-free and therapy-free versus 11% on placebo during six-month evaluation
- Key secondary endpoints showed 89% fewer treated attacks, 91% fewer moderate/severe attacks, and clinically meaningful quality-of-life improvement
- Safety profile favorable: all treatment-emergent adverse events mild or moderate, with no serious adverse events in the lonvo-z arm
- Rolling BLA began in April; Intellia targets FDA approval and U.S. launch in the first half of 2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Intellia Therapeutics, Inc. 8-K filings
Get the next NTLA 8-K as it lands
Follow NTLA for push alerts, or ask the research agent what this filing means.